---
title: "LabTech's net profit for the year 2024 is 39.7131 million yuan, a year-on-year increase of 44.08%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229549200.md"
description: "LabTech released its 2024 annual performance preliminary report, with total operating revenue of 424 million yuan, a year-on-year increase of 2.01%; net profit of 39.7131 million yuan, a year-on-year increase of 44.08%; net profit excluding non-recurring gains and losses of 31.5286 million yuan, a year-on-year increase of 35.31%; basic earnings per share of 0.59 yuan. During the reporting period, the comprehensive gross profit margin rebounded, and period expenses were kept under stable control"
datetime: "2025-02-25T09:04:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229549200.md)
  - [en](https://longbridge.com/en/news/229549200.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229549200.md)
---

# LabTech's net profit for the year 2024 is 39.7131 million yuan, a year-on-year increase of 44.08%

According to the Zhitong Finance APP, LabTech (688056.SH) released its performance report for the fiscal year 2024. The total operating revenue for 2024 is 424 million yuan, a year-on-year increase of 2.01%; the net profit attributable to the parent company's owners is 39.7131 million yuan, a year-on-year increase of 44.08%; the net profit attributable to the parent company's owners after deducting non-recurring gains and losses is 31.5286 million yuan, a year-on-year increase of 35.31%; the basic earnings per share is 0.59 yuan.

In the same period last year, the comprehensive gross profit margin of all products declined due to rising raw material costs and the commissioning of new production lines; there were no new production capacities added in this reporting period, and raw material costs have stabilized, eliminating these cost-influencing factors, leading to a recovery in the annual comprehensive gross profit margin. At the same time, the company has strengthened control over overall cost management, improved employee work efficiency, and successfully achieved stable control of period expenses during the reporting period, with no increase observed

### Related Stocks

- [688056.CN](https://longbridge.com/en/quote/688056.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Americans face worsening food quality and rising grocery costs](https://longbridge.com/en/news/287152199.md)
- [India's lifeline ferry across strategic archipelago](https://longbridge.com/en/news/286716580.md)
- [TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement](https://longbridge.com/en/news/286833781.md)
- [Agnico Eagle CEO bets on Arctic barge shipping to keep costs low at Hope Bay gold mine](https://longbridge.com/en/news/287124816.md)